Table 1. List of clinical trials included in the meta-analysis.

	Reference	Ph	Masking	Histology	No.	Treatment arms
Nivolumab
1	Brahmer J. et al. (2015)	3	Open-label	NSCLC (Sq)	272	Nivolumab
						Docetaxel
2	Borghaei H. et al. (2015)	3	Open-label	NSCLC (Non-Sq)	582	Nivolumab
						Docetaxel
3	Motzer RJ. et al. (2015)	3	Open-label	Renal	821	Nivolumab
						Everolimus
4	Ferris RL. et al. (2016)	3	Open-label	Head&Neck	361	Nivolumab
						MTX/Docetaxel/Cetuximab
5	Robert C. et al. (2015)	3	Double-blind	Melanoma	418	Nivolumab
						Dacarbazine
6	Weber JS. et al. (2015)	3	Open-label	Melanoma	405	Nivolumab
						Chemotherapy
Pembrolizumab
7	Herbst RS. et al. (2016)	2/3	Open-label	NSCLC (PDL1 > 1%)	1034	Pembrolizumab 2 mg/Kg
						Pembrolizumab 10 mg/kg
						Docetaxel
8	Ribas A. et al. (2015)	2	Open-label	Melanoma	540	Pembrolizumab 2 mg/kg
						Pembrolizumab 10 mg/kg
						Chemotherapy
9	Reck M. et al. (2016)	3	Open-label	NSCLC (PDL1 > 50%)	305	Pembrolizumab
						Chemotherapy
10	Bellmunt J. et al. (2017)	3	Open-label	Urothelial carcinoma	542	Pembrolizumab
						Docetaxel/Paclitaxel/Vinflunine
Atezolizumab
11	Fehrenbacher L. et al. (2016)	2	Open-label	NSCLC	287	Atezolizumab
						Docetaxel
12	Rittmeyer A. et al. (2016)	3	Open-label	NSCLC	850	Atezolizumab
						Docetaxel